A meningitis B outbreak in Kent has triggered a surge in demand for vaccines across southeast England, following the deaths of two people, and has ignited calls for broader adolescent immunization.
Residents who may have been exposed can receive the vaccine and preventive antibiotics through the UK Health Security Agency (UKHSA) at university buildings, clinics, and GP offices.
Pharmacies Struggle to Meet Demand
The National Pharmacy Association (NPA) said pharmacies have been “inundated” with requests for MenB vaccines. Major chains, including Boots and Superdrug, reported shortages and implemented online waiting lists.
The government released 20,000 NHS doses for the private market to ease pressure, but the NPA warned this may not meet demand. The vaccines available include GSK’s Bexsero and Pfizer’s Trumenba, both costing around £200 ($267) privately.
Current NHS Coverage and Teen Debate
Since 2015, infants have received the MenB vaccine on the NHS, the group at highest risk. Teenagers, the second-highest risk group, currently receive vaccines only for other meningitis strains.
Experts say there is no harm in getting the vaccine, but antibiotics remain the fastest protection for those who may have been exposed. Brendan Wren, co-director of the London School of Hygiene and Tropical Medicine Vaccine Centre, noted immunity from the two-dose vaccine takes a month to develop.
The outbreak has prompted Health Secretary Wes Streeting to ask the Joint Committee on Vaccination and Immunisation (JCVI) to re-evaluate eligibility criteria, though recommendations are based on cost-benefit analysis. Tom Nutt, chief executive of Meningitis Now, stressed the moral case for expanding access to teenagers.
While the Kent outbreak of 29 cases is unusually high, experts caution it may not immediately alter JCVI policy unless similar outbreaks continue.
